Orchard Therapeutics plc (ORTX): Price and Financial Metrics

Orchard Therapeutics plc (ORTX): $16.70

0.05 (+0.30%)

POWR Rating

Component Grades

Momentum

D

Stability

D

Sentiment

Quality

D

Add ORTX to Watchlist
Sign Up

Industry: Medical - Pharmaceuticals

Industry

NR

Ranked

#91 of NR

in industry

ORTX Price/Volume Stats

Current price $16.70 52-week high $16.72
Prev. close $16.65 52-week low $4.24
Day low $16.63 Volume 372,300
Day high $16.72 Avg. volume 157,287
50-day MA $16.32 Dividend yield N/A
200-day MA $9.40 Market Cap 380.11M

ORTX Stock Price Chart Interactive Chart >


Orchard Therapeutics plc (ORTX) Company Bio


Orchard Therapeutics Plc is a biopharmaceutical company, which engages in the discovery, acquisition, development, and commercialization of gene therapies. The company focuses on its autologous ex vivo gene therapy approach on three therapeutic rare disease franchise areas: primary immune deficiencies, neurometabolic disorders, and hemoglobinopathies. Its portfolio includes Strimvelis, a commercial-stage gamma retroviral-based product for the treatment of Adenosine deaminase deficiency (ADA-SCID). It operates through the United Kingdom and United States geographical segments. The company was founded in August 2018 and is headquartered in London, the United Kingdom.


ORTX Latest News Stream


Event/Time News Detail
Loading, please wait...

ORTX Latest Social Stream


Loading social stream, please wait...

View Full ORTX Social Stream

Latest ORTX News From Around the Web

Below are the latest news stories about ORCHARD THERAPEUTICS PLC that investors may wish to consider to help them evaluate ORTX as an investment opportunity.

Orchard adds ~32% as FDA clears trial for metabolic disorder drug

  • Orchard Therapeutics (NASDAQ:ORTX) announced Thursday that the FDA cleared its Investigational New Drug (IND) application for OTL-203, targeted at the neurometabolic disease, Hurler subtype of mucopolysaccharidosis type I (MPS-IH).
  • Orchard (ORTX), a biotech focused on gene therapies, climbed ~32% pre-market in reaction. 
  • The company plans to evaluate OTL-203 against the standard of care in a global re...

    Seeking Alpha | January 5, 2023

Read More 'ORTX' Stories Here

ORTX Price Returns

1-mo N/A
3-mo 1.58%
6-mo 4.44%
1-year 233.00%
3-year -72.26%
5-year -90.98%
YTD 1.52%
2023 343.40%
2022 -71.89%
2021 -69.44%
2020 -68.58%
2019 -12.59%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!